October 23, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia October 22, 2026 16:05 ET  | Source: Fortrea Holdings Inc Highlights DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening

October 22, 2026 07:30 ET  | Source: Boehringer Ingelheim Cologne, Germany – Boehringer Ingelheim and Microsoft today announced a strategic collaboration that aims to bring safe and effective therapies to patients sooner fueled by AI. The collaboration will focus on jointly investigating the potential of Digital Patient Twins in clinical development. Digital Patient Twins are

Asimov’s CHO Edge System, including the recently announced Chrysalis transposase and Kernel, Asimov’s AI-driven genetic design software, will support LG Chem’s biologics cell line development activities October 21, 2026 19:00 ET  | Source: Asimov BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today

October 21, 2026 09:48 ET  | Source: Egg Medical, Inc. MINNEAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Egg Medical today announced the publication of a prospective study in the Journal of the American Heart Association (JAHA) evaluating its EggNest Enhanced Radiation Protection Devices (ERPDs). Conducted at The Christ Hospital in Cincinnati, OH, the real-world clinical

October 20, 2026 10:00 ET  | Source: Circle Cardiovascular Imaging Inc. CALGARY, Alberta, Oct. 20, 2026 (GLOBE NEWSWIRE) — Circle Cardiovascular Imaging (Circle CVI), a provider of AI-enabled cardiovascular imaging software, today announced its participation in EXIT-CVD, a five-year research project bringing together 42 public and private partners across 17 countries. Co-funded by the European

October 20, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013)

October 19, 2026 09:00 ET  | Source: VIVUS B.V. Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments

October 19, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and

Callio leaders delivered three presentations and two panel discussions on dual-payload ADC resistance, manufacturability, linker design, and the path to next-generation ADCs October 15, 2026 08:00 ET  | Source: Callio Therapeutics SAN DIEGO, SEATTLE and SINGAPORE, Oct. 15, 2026 (GLOBE NEWSWIRE) — Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 October 15, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced

October 15, 2026 04:00 ET  | Source: Royal Philips October 15, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and the industry partners. The research consortium is

October 14, 2026 09:05 ET  | Source: Kyowa Kirin, Inc. PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the publication of three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) in the Journal of

October 14, 2026 08:00 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in

Based on verified customer reviews, the recognition spans Cority’s environmental health and safety and occupational health and safety solutions October 14, 2026 08:00 ET  | Source: Cority Software Inc. TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) — Cority, the intelligent EHS+ platform that helps customers see and prevent risks across their operations, announced today that it